BLTEBelite Bio Inc
Slide 1 of 3
Company Overview
Name
Belite Bio Inc
52W High
$125.24
52W Low
$49.00
Market Cap
$3.8B
Dividend Yield
0%
Price/earnings
-1.18
P/E
-1.18
Dividends
No dividend
Sentiment
Score
Bullish
75
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 2 of 3
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
$-40M
Net Income
$-36.1M
EV to EBITDA
$0.00
EV to Revenue
$0.00
Price to Book value
$26.27
Price to Earnings
$0.00
Additional Data
Selling, General & Admin Expense
$10.1M
Research & Development Expense
$29.9M
Total Operating Expenses
$-40M
Interest Expense
$-20K
Interest & Investment Income
$3.7M
Other Income / (Expense), net
$141K
Slide 3 of 3
Earnings History
Estimated EPS
Reported EPS
N/A Slide 1 of 5
Company Overview
Name
Belite Bio Inc
52W High
$125.24
52W Low
$49.00
Market Cap
$3.8B
Dividend Yield
0%
Price/earnings
-1.18
P/E
-1.18
Dividends
No dividend
Slide 2 of 5
Sentiment
Score
Bullish
75
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 3 of 5
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
$-40M
Net Income
$-36.1M
EV to EBITDA
$0.00
EV to Revenue
$0.00
Price to Book value
$26.27
Price to Earnings
$0.00
Slide 4 of 5
Additional Data
Selling, General & Admin Expense
$10.1M
Research & Development Expense
$29.9M
Total Operating Expenses
$-40M
Interest Expense
$-20K
Interest & Investment Income
$3.7M
Other Income / (Expense), net
$141K
Slide 5 of 5
Earnings History
Estimated EPS
Reported EPS
N/AUpcoming Earnings
We were not able to find an announced earnings date for this symbol yet. Check back again later
Company Info
CEO
Yue H. Lin
Location
California, USA
Exchange
Nasdaq
Website
https://belitebio.com
Summary
Belite Bio, Inc engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases.
Company Info
CEO
Yue H. Lin
Location
California, USA
Exchange
Nasdaq
Website
https://belitebio.com
Summary
Belite Bio, Inc engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases.
